On October 7, 2026, a trial listing involving angiotensin II related heart failure management was updated to recruiting status. The trial, titled "A Village Doctor-led Telehealth Supported Improvement of Outcomes of AF Patients With Heart Failure Due to Reduced or Preserved Ejection Fraction: The MIRACLE-AF 2 Heart Failure Management Trial (MIRACLE AF-HF)," is registered under ID NCT07492524.
The trial phase is listed as not applicable. Its current status is recruiting, according to the ClinicalTrials.gov record dated October 7, 2026. The study focuses on telehealth-supported management for patients with atrial fibrillation who also have heart failure, whether due to reduced or preserved ejection fraction.
No results, outcomes, or efficacy data have been posted for this trial at this stage. The listing reflects only the recruiting status and trial design details as registered. Angiotensin II remains an approved compound, and this update pertains solely to the trial's recruitment phase rather than any new clinical findings.
Readers interested in background on angiotensin II, including its approved uses and general profile, can consult the compound overview for additional context.